You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Details for Patent: 9,937,181

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,937,181 protect, and when does it expire?

Patent 9,937,181 protects XELJANZ XR and is included in one NDA.

This patent has forty-eight patent family members in twenty-four countries.

Summary for Patent: 9,937,181

Scope and claims summary:

Title:	Tofacitinib oral sustained release dosage forms
Abstract:	The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Inventor(s):	Herbig; Scott Max (East Lyme, CT), Krishnaswami; Sriram (East Lyme, CT), Kushner, IV; Joseph (Bradford, RI), Lamba; Manisha (Waterford, CT), Stock; Thomas C (Chester Springs, PA)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	14/211,659
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,937,181
Patent Claim Types: see list of patent claims	Formulation; Compound; Delivery; Device; Dosage form;

Drugs Protected by US Patent 9,937,181

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,937,181

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095487	⤷ Subscribe
Australia	2014233850	⤷ Subscribe
Australia	2017203334	⤷ Subscribe
Brazil	112015020453	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.